Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EOS-984
EOS301984 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A dose escalation | EXPERIMENTAL | EOS301984 dose escalation as monotherapy |
| Part 1B dose escalation | EXPERIMENTAL | EOS301984 in combination with other cancer therapies |
| Name | Type | Description |
|---|---|---|
| EOS301984 | DRUG | Multiple doses of EOS301984 |
| Anti-PD-1 monoclonal antibody | DRUG | Multiple doses of EOS301984 in combination with Anti-PD-1 |
INCLUSION CRITERIA * Provide a signed written informed consent before any study-specific evaluation. * Be at least 18 years old on the day of signing informed consent. * Have a histologically confirmed advanced solid tumor for which no standard approved treatment is available, or are ineligible for...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EOS301984 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development as a potential therapy for adult patients with advanced solid tumors.
EOS301984 targets PD-1, an immune checkpoint protein. By targeting PD-1, EOS301984 is designed to modulate the immune system's response against cancer cells, potentially enhancing the body's ability to fight tumors.
EOS301984 is being developed by iTeos Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of EOS301984 in patients with advanced solid tumors.
EOS301984 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is a first-in-human study assessing the drug as a monotherapy or in combination therapy.
EOS301984 is being studied in a Phase 1 clinical trial with the identifier NCT06547957. This first-in-human study is evaluating EOS301984 as monotherapy or combination therapy in adult participants with advanced solid tumors. The trial is active but not recruiting and is being conducted in Belgium.
No alternative names for EOS301984 have been disclosed. The drug is being developed under the name EOS301984 by iTeos Therapeutics, Inc. and is currently in Phase 1 clinical trials for advanced solid tumors.